Innovating Works

REGENERBONE

Financiado
REGENERATING LARGE BONE DEFECTS
In the field of orthopedics and maxillo-facial surgeries, there is still no satisfying solution to repair critical size bone defects. Autograft, which is the current gold standard, presents several drawbacks, including prolonged p... In the field of orthopedics and maxillo-facial surgeries, there is still no satisfying solution to repair critical size bone defects. Autograft, which is the current gold standard, presents several drawbacks, including prolonged pain on donor site and higher infection risks. It needs to be replaced by efficient, safe and easy-to-use strategies. Some synthetic bone grafts are providing mechanical and osteoconductive properties, but there is a need to introduce a bioactive molecules, such as a growth factor or a peptide, to trigger actively bone repair. These orthobiologics products are appealing since they trigger stem cell activation in situ. There are several approved products containing orthobiologics on the market for bone regeneration, but the physiological delivery of orthobiologics remains a challenge: severe adverse effect have been reported due to the supra-physiological dose of biologics used. In addition these product do not provide structural properties which is necessary for critical size defect reconstruction. Ideally the carrier for the bioactive molecules should be appropriate and enable a spatially/temporally-controlled molecules delivery with physiological dose. Our nanomedicine technology consists of an osteoinductive biomimetic films that can be deposited on architectured implant of any shape and material (ceramics, polymers, metals). The aim of REGENERBONE is to advance our technology toward a clinical application in maxilla-facial surgery and orthopedics. This will be done by conducting pre-clinical trials in large animals, doing a market search, securing the sourcing of the film components and building a business model. The successful results we obtained recently in the frame of the ERC BIOMIM and Proof-of-Concept OSCODI are the basis for REGENERBONE, which goes a step beyond in the long process of introducing an innovative medical device to the market in an era of personalized medicine. ver más
30/09/2019
INP GRENOBLE
150K€
Perfil tecnológico estimado
Duración del proyecto: 18 meses Fecha Inicio: 2018-03-22
Fecha Fin: 2019-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2017-PoC: ERC-Proof of Concept
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
INSTITUT POLYTECHNIQUE DE GRENOBLE No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5